Stilla

Stilla Technologies adds 20 new oncology liquid biopsies kits to its reagents portfolio from partner ApexBio

Retrieved on: 
Tuesday, April 18, 2023
Biotechnology, Health, Clinical Trials, Medical Supplies, Oncology, DNA, Circulating tumor DNA, AACR, University, Annual, Liquid biopsy, Research, Biomarker, National and Kapodistrian University of Athens, Promega, Dicarboxylic acid, Neoplasm, American Association for Cancer Research, PCR, Medical imaging, Pharmaceutical industry, Stilla

Stilla Technologies today announced the availability of 20 new digital PCR assays, optimized for its Crystal Digital PCR™ platform, the naica® system, to be utilized for the detection of circulating tumor DNA (ctDNA) from liquid biopsy samples.

Key Points: 
  • Stilla Technologies today announced the availability of 20 new digital PCR assays, optimized for its Crystal Digital PCR™ platform, the naica® system, to be utilized for the detection of circulating tumor DNA (ctDNA) from liquid biopsy samples.
  • Produced by distributor and technology partner ApexBio, these digital PCR kits are designed for the absolute quantitation of nucleic acids from genetic mutations found across a widespread range of oncological indications.
  • The company offers off-the-shelf digital PCR kits for use on the naica® system, as well as assay development services for custom assay design.
  • More information on Stilla product offerings and scientific posters can be obtained at Stilla’s exhibition booth #3172 from our scientific specialists.

Stilla Technologies and Atila BioSystems to Co-Develop High-Plex Digital PCR Kits for Oncology

Retrieved on: 
Thursday, March 30, 2023
Research, Medical Devices, Health Technology, Biotechnology, Other Health, Health, General Health, Science, Oncology, DNA, Circulating tumor DNA, Liquid biopsy, Breast, Prostate, Doctor of Philosophy, Lung, Hereditary nonpolyposis colorectal cancer, RUO, Patient, Melanoma, Diagnosis, Neoplasm, PCR, Medical imaging, Atila, Stilla

Stilla Technologies and Atila BioSystems today announced an agreement to market digital PCR kits and assays produced by Atila BioSystems for use on the naica® system (Stilla Technologies) .

Key Points: 
  • Stilla Technologies and Atila BioSystems today announced an agreement to market digital PCR kits and assays produced by Atila BioSystems for use on the naica® system (Stilla Technologies) .
  • The digital PCR kits, optimized specifically for use with the 6-color naica® system, will be utilized for the detection of circulating tumor DNA (ctDNA) from liquid biopsy samples taken from patients with high-occurring cancer indications such as breast, lung, melanoma, prostate, and colorectal cancers.
  • The co-labeled digital PCR kits will be promoted globally by Atila and Stilla and will be designed For Research Use Only (RUO) applications.
  • “Among digital PCR instruments, Stilla’s naica® system offers the industry’s highest level of multiplexing and sensitivity, making the platform ideally suited to detect rare mutations in complex samples,” notes Youxiang Wang, PhD, CEO at Atila BioSystems.

New Stilla Ruby Chip and naica® system 21 CFR Part 11 compliance enable full automation of digital PCR testing for clinically-oriented applications

Retrieved on: 
Monday, March 20, 2023
Oncology, Health, Infectious Diseases, Genetics, Research, Science, SBS, DNA, Circulating tumor DNA, Workflow, Liquid biopsy, CFR, Promega, Nested polymerase chain reaction, Title 21 CFR Part 11, Quality control, Neoplasm, PCR, Stilla

Stilla Technologies, the multiplex digital PCR company , has recently introduced the Ruby Chip , the industry’s first ‘load-and-go’ consumable for digital PCR, optimized for its naica® system.

Key Points: 
  • Stilla Technologies, the multiplex digital PCR company , has recently introduced the Ruby Chip , the industry’s first ‘load-and-go’ consumable for digital PCR, optimized for its naica® system.
  • The naica® system , which now supports 21 CFR Part 11 regulatory compliance, is part of a fully-automated sample-to-results workflow – the first of its kind for digital PCR.
  • A key feature of the Ruby Chip is that it comes ready-to-use and preloaded with sealed chambers, enabling the addition of sample mix in a single, foil-piercing pipetting step.
  • Notes Dangla, “As an example of our capability, we are partnering with Promega Corporation to create a fully automated solution for digital PCR analysis.

Global Digital PCR Market Analysis and Forecast, 2022-2032: Rising Awareness of d-PCR-based Diagnostic Testing and Significant Funding for Executing R&D - ResearchAndMarkets.com

Retrieved on: 
Friday, September 9, 2022
Biotechnology, General Health, Health Technology, Health, COVID-19, Criticality, Applied Biosystems, Promega, Research, Digital, Awareness, EMEA, City, R, Polymerase, Health, Diagnosis, IVD, Workflow, Investment, Region, PCR, Thermo Fisher Scientific, Prevalence, Biotechnology, CAGR, Liquid biopsy, Country, Drug discovery, Growth, Digital polymerase chain reaction, Video game, Medical device, Pharmaceutical industry, Stilla

Most players in the global digital PCR market offer products, such as kits and assays, systems, and reagents and consumables.

Key Points: 
  • Most players in the global digital PCR market offer products, such as kits and assays, systems, and reagents and consumables.
  • Increasing investments in R&D for d-PCR molecular diagnostics is one of the major opportunities in the global digital PCR market.
  • The current global digital PCR market comprises kits and assays, system, and reagents and consumables.
  • The global digital PCR market based on the product segment was dominated by kits and assays in 2021.

Global Digital PCR Market to Reach $2.84 Billion by 2032 - BIS Research Study

Retrieved on: 
Tuesday, August 23, 2022
Technology, Promega, Research, Digital, Genetics, EMEA, Digital polymerase chain reaction, Infection, Workflow, PCR, Liquid biopsy, Drug discovery, Adoption, Pharmaceutical industry, Stilla

FREMONT, Calif., Aug. 23, 2022 /PRNewswire/ -- BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled Digital PCR Market – A Global and Regional Analysis. 

Key Points: 
  • The massively parallel methods transcending digital PCR-based molecular diagnostics further enable absolute quantification through partitioning the reaction.
  • In addition, the advantages of digital PCR over conventional PCR, such as real-time PCR (RT-PCR), and its rising adoption is anticipated to grow further in the coming years."
  • In October 2021, Bio-Rad Laboratories, Inc. acquired Dropworks, Inc., a development stage company focused on developing a digital PCR product.
  • Digital PCR has seen its application largely in the following segments:

Stilla Technologies Solidifies Leadership in EMEA, Expands Footprint in APAC

Retrieved on: 
Tuesday, August 2, 2022
General Health, Health, Science, Other Science, Research, Food, Genomics, Industry, Twitter, DKSH, Caliper Life Sciences, CEO, Research, Infection, Multimedia, EMEA, Proteomics, Cancer, Technology, FUJIFILM, ITS, YouTube, LinkedIn, PCR, PerkinElmer, Management, Sergeant, Stilla, Eppendorf

Stilla Technologies, the multiplex digital PCR company, announces the addition of Yvan Sergeant to serve in the capacity of Vice President/General Manager for the EMEA region.

Key Points: 
  • Stilla Technologies, the multiplex digital PCR company, announces the addition of Yvan Sergeant to serve in the capacity of Vice President/General Manager for the EMEA region.
  • Yvan held prior leadership positions at PerkinElmer, Caliper Life Sciences, and Trinean, and comes to Stilla from Quanterix where he served as VP/GM, Europe.
  • Along with the addition of Sergeant, Stilla Technologies also announces several new distribution partnerships in Asia.
  • With today's addition of six strategic partners in APAC, Stilla substantially increases its global market presence, and strengthens its ability to serve customers globally, notes Philippe Mourere, President and CEO of Stilla Technologies.

Stilla and Promega Announce Co-Marketing Agreement to Offer Complete Digital PCR Workflow Solution

Retrieved on: 
Wednesday, April 6, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Medical Devices, LinkedIn, Partnership, HER2, PCR, AACR, NGS, Research, PIK3CA, American Association, Technology, Cancer, CEO, EGFR, Â, Promega, American Association for Cancer Research, Association, Infection, Twitter, Liquid biopsy, Workflow, EMEA, Polymerase, Drug discovery, VP, YouTube, Maxwell, Breast cancer, Food, Large-cell lung carcinoma, Medical imaging, Stilla

Stilla Technologies , the multiplex digital PCR company, and Promega Corporation today announced a co-marketing agreement that combines sample preparation with the latest Maxwell systems and digital PCR on the six-color naica system .

Key Points: 
  • Stilla Technologies , the multiplex digital PCR company, and Promega Corporation today announced a co-marketing agreement that combines sample preparation with the latest Maxwell systems and digital PCR on the six-color naica system .
  • Representative data of the liquid biopsy workflow will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 on April 10, 2022.
  • The strategic partnership with Promega enhances our value proposition by bringing a fully-validated sample-to-answer solution for biomarker testing, said Philippe Mourre, President and CEO, Stilla Technologies.
  • Stillas groundbreaking Crystal Digital PCR solution, the naica system , is the industrys first digital PCR system featuring six fluorescent channels, providing biomedical researchers and clinicians the highest multiplexing and detection capacity available on the market.

Stilla Technologies Expands EMEA Footprint with New Distribution Partnerships

Retrieved on: 
Tuesday, March 22, 2022
Oncology, Health, Infectious Diseases, Genetics, Other Science, Research, Science, LinkedIn, AH, Commercial Operating System (COS), PCR, Alliance Global, Doctor of Philosophy, Research, Technology, Cancer, Infection, Twitter, EMEA, Solution, YouTube, SEM, Food, History, Stilla

With the expanded global availability of our powerful digital PCR solution, Stilla is answering scientists demand for faster turnaround time, higher precision and sensitivity, said Matthew Grow, PhD, Vice President Global Marketing and Commercial Operations, Stilla Technologies.

Key Points: 
  • With the expanded global availability of our powerful digital PCR solution, Stilla is answering scientists demand for faster turnaround time, higher precision and sensitivity, said Matthew Grow, PhD, Vice President Global Marketing and Commercial Operations, Stilla Technologies.
  • With U.S. headquarters in Boston, MA, and European headquarters in Paris, France, Stillas expanded global distribution comes on the heels of the global launch of its six-color naica system.
  • Stilla has U.S. headquarters in Boston, MA, European headquarters in Paris, France, and strategic distribution and business partnerships in China and throughout EMEA.
  • To learn more, visit www.stillatechnologies.com and connect with Stilla on Twitter , LinkedIn and YouTube .

Four Seasons Shares New Must-See Destinations For 2022

Retrieved on: 
Tuesday, November 30, 2021
Momentum, Michelin, Bed, Royal, Beverly Wilshire Hotel, Global Operations, Resort, Collection, Four Seasons, Kingdom Centre, Travel, Heart, Time, ARGO, Anahita, Airbus, Nicollet Mall, Four Seasons Hotel Houston, Food, Stilla, Chao Phraya River, Four Seasons Hotels and Resorts, Chat, Health, Four Seasons Hotel and Private Residences New Orleans, Accor, Multimedia, Sunshine State, Four Seasons Hotel & Private Residences, One Dalton Street, Hotel, Industry, Residence, Business, City, Landaa Giraavaru, Family, Wine, NOLA, Instagram, Privacy, Gallery, Four Seasons Resort Lanai, Tourism, Restaurant, Interior design

"Momentum continues to build across Four Seasons extraordinary global portfolio as we introduce new destinations and elevate some of our most iconic properties with a new look and feel."

Key Points: 
  • "Momentum continues to build across Four Seasons extraordinary global portfolio as we introduce new destinations and elevate some of our most iconic properties with a new look and feel."
  • Clerc continues: "As we gear up for 2022, we invite travellers to rediscover their love of exploration, together with Four Seasons.
  • San Domenico Palace, Taormina, A Four Seasons Hotel Explore the best of Sicily at the legendary San Domenico Palace, now officially a Four Seasons experience.
  • Four Seasons Mobile App and Chat also provides a convenient and contactless way for individuals to customise their stay.

Stilla Technologies Strengthens Executive Team with Appointment of Matthew Grow, PhD, to Vice President Global Marketing and Commercial Operations

Retrieved on: 
Wednesday, June 30, 2021
Biotechnology, Technology, Health, Pharmaceutical, Oncology, Other Science, Research, Infectious diseases, Nanotechnology, Genetics, Science, Articles, Science and technology, Biology, Molecular biology, Biotechnology, Amplifiers, Laboratory techniques, Abcam, Stilla, Agilent Technologies, Polymerase chain reaction

Stilla Technologies , the company innovating the next generation of digital PCR solutions for life science research and clinical diagnostics, today announced the appointment of Matthew Grow, PhD, to Vice President of Global Marketing and Commercial Operations.

Key Points: 
  • Stilla Technologies , the company innovating the next generation of digital PCR solutions for life science research and clinical diagnostics, today announced the appointment of Matthew Grow, PhD, to Vice President of Global Marketing and Commercial Operations.
  • View the full release here: https://www.businesswire.com/news/home/20210630005367/en/
    Matthew Grow, PhD, Vice President Global Marketing and Commercial Operations, Stilla Technologies (Photo: Business Wire)
    We are thrilled to welcome Matt on board as Stilla looks to become a mainstay force across the global genomics research and genetic testing markets, said Philippe Mourere, President and CEO, Stilla Technologies.
  • His solid track record of commercializing multiplex platforms and building core commercial teams will serve Stilla well as we enter our next phase of development.
  • Dr. Grow joins Stilla Technologies from Abcam where he led the successful launch and growth of the companys portfolio of proteomic and genomic multiplex platforms and assays.